Search
forLearn
5 / 801 resultslearn Setipiprant
learn Calcipotriene
learn phenoxyethanol
learn TeraCeutic™
Research
5 / 1000+ results
research Transfollicular Drug Delivery: Penetration of Drugs Through Human Scalp Skin and Comparison of Penetration Between Scalp and Abdominal Skins In Vitro
Drugs penetrate scalp skin better than abdominal skin, with scalp hair follicles aiding in higher drug delivery.
research Impact of Ester Promoieties on Transdermal Delivery of Ketorolac
Balancing lipophilicity and solubility is key for effective and safe ketorolac prodrugs.
research Inhibition of the pro-oxidant effects of benoxaprofen on poiymorpbonuclear leucocytes by retinol acetate in vitro
Retinol acetate can reduce the harmful effects of the drug benoxaprofen on white blood cells.
research FEATURES
Pharmacists play a key role in helping patients use over-the-counter products correctly, including those for hair regrowth and smoking cessation.
research Postmenopausal frontal fibrosing alopecia: A frontal variant of lichen planopilaris
Frontal fibrosing alopecia is a hair loss condition in postmenopausal women, similar to lichen planopilaris, with ineffective treatments.
Community Join
5 / 1000+ resultscommunity Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Kintors interim report from 9-2-24 for everyone whos interested
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
community Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.